title: Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease.
abstract: The Alzheimer's disease (AD) epidemic is a looming crisis, with an urgent need for new therapies to delay or prevent symptom onset and progression. There is growing awareness that clinical trials must target stage-appropriate pathophysiological mechanisms to effectively develop disease-modifying treatments. Advances in AD biomarker research have demonstrated changes in amyloid-beta (Aβ), brain metabolism and other pathophysiologies prior to the onset of memory loss, with some markers possibly changing one or two decades earlier. These findings suggest that amyloid-based therapies would optimally be targeted at the earliest clinically detectable stage (such as mild cognitive impairment (MCI)) or before. Postmortem data indicate that tau lesions in the locus coeruleus (LC), the primary source of subcortical norepinephrine (NE), may be the first identifiable pathology of AD, and recent data from basic research in animal models of AD indicate that loss of NE incites a neurotoxic proinflammatory condition, reduces Aβ clearance and negatively impacts cognition - recapitulating key aspects of AD. In addition, evidence linking NE deficiency to neuroinflammation in AD also exists. By promoting proinflammatory responses, suppressing anti-inflammatory responses and impairing Aβ degradation and clearance, LC degeneration and NE loss can be considered a triple threat to AD pathogenesis. Remarkably, restoration of NE reverses these effects and slows neurodegeneration in animal models, raising the possibility that treatments which increase NE transmission may have the potential to delay or reverse AD-related pathology. This review describes the evidence supporting a key role for noradrenergic-based therapies to slow or prevent progressive neurodegeneration in AD. Specifically, since MCI coincides with the onset of clinical symptoms and brain atrophy, and LC pathology is already present at this early stage of AD pathogenesis, MCI may offer a critical window of time to initiate novel noradrenergic-based therapies aimed at the secondary wave of events that lead to progressive neurodegeneration. Because of the widespread clinical use of drugs with a NE-based mechanism of action, there are immediate opportunities to repurpose existing medications. For example, NE transport inhibitors and NE-precursor therapies that are used for treatment of neurologic and psychiatric disorders have shown promise in animal models of AD, and are now prime candidates for early-phase clinical trials in humans.
authors: Neuroscience Graduate Program, Emory University, Atlanta, GA 30322, USA.
authors: Termpanit
authors: T
authors: Chalermpalanupap
authors: Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
authors: Becky
authors: B
authors: Kinkead
authors: Department of Neurology, Suite 6000 WMB, 101 Woodruff Circle, Emory University School of Medicine, Atlanta, GA 30322, USA.
authors: William T
authors: WT
authors: Hu
authors: Department of Neurology, Clinical Neurosciences, University of Bonn, 53127 Bonn, Germany.
authors: Markus P
authors: MP
authors: Kummer
authors: Department of Neurology, Clinical Neurosciences, University of Bonn, 53127 Bonn, Germany.
authors: Thea
authors: T
authors: Hammerschmidt
authors: Department of Neurology, Clinical Neurosciences, University of Bonn, 53127 Bonn, Germany.
authors: Michael T
authors: MT
authors: Heneka
authors: Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA.
authors: David
authors: D
authors: Weinshenker
authors: Department of Neurology, Suite 6000 WMB, 101 Woodruff Circle, Emory University School of Medicine, Atlanta, GA 30322, USA.
authors: Allan I
authors: AI
authors: Levey
references: Neuron. 2013 Mar 6;77(5):929-41
references: 23473322
references: Am J Psychiatry. 1989 Jan;146(1):45-9
references: 2643356
references: Am J Geriatr Psychiatry. 2009 Sep;17(9):752-9
references: 19700948
references: Biol Psychiatry. 2013 Mar 1;73(5):454-63
references: 22883210
references: Neurobiol Aging. 2004 Aug;25(7):853-9
references: 15212839
references: Am J Psychiatry. 1997 Jan;154(1):25-30
references: 8988954
references: Acta Neuropathol. 2011 May;121(5):589-95
references: 21516512
references: BMC Med Genet. 2010 Nov 11;11:162
references: 21070631
references: Biomark Med. 2010 Feb;4(1):27-36
references: 20383271
references: Acta Neuropathol. 2010 Sep;120(3):385-99
references: 20652578
references: Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8712-6
references: 8378353
references: Neuroscience. 2005;135(4):1295-307
references: 16165282
references: Pharmacol Ther. 2007 Mar;113(3):523-36
references: 17303246
references: Acta Neuropathol. 2010 Jun;119(6):669-78
references: 20232070
references: Neurosci Res. 1995 Jul;22(4):399-409
references: 7478305
references: Annu Rev Neurosci. 2009;32:267-87
references: 19555290
references: Nat Rev Neurosci. 2009 Mar;10(3):211-23
references: 19190638
references: Nat Med. 2006 Sep;12(9):1005-15
references: 16960575
references: J Alzheimers Dis. 2013;33(4):1147-56
references: 23128558
references: Br J Psychiatry. 1994 Jul;165(1):53-9
references: 7953058
references: Ann Neurol. 1992 Nov;32(5):667-76
references: 1449247
references: Neurochem Int. 2002 Nov;41(5):357-65
references: 12176079
references: Behav Brain Funct. 2005 Oct 03;1:16
references: 16202140
references: Biol Psychiatry. 1999 Nov 1;46(9):1219-33
references: 10560027
references: Neurobiol Aging. 2007 Aug;28(8):1206-14
references: 16837104
references: Arch Gen Psychiatry. 1995 Sep;52(9):774-82
references: 7654129
references: Am J Geriatr Psychiatry. 2008 Nov;16(11):883-92
references: 18978249
references: Neurobiol Aging. 2012 Aug;33(8):1651-63
references: 21705113
references: J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):278-9
references: 16421143
references: Acta Neuropathol. 2011 Feb;121(2):171-81
references: 21170538
references: Curr Alzheimer Res. 2008 Jun;5(3):342-5
references: 18537547
references: Sleep Med Rev. 2012 Apr;16(2):187-97
references: 22296742
references: Int J Neuropsychopharmacol. 2010 Mar;13(2):243-56
references: 19849892
references: Brain Res Brain Res Rev. 2003 Apr;42(1):33-84
references: 12668290
references: Mov Disord. 2009 Jan 30;24(2):277-82
references: 19025777
references: Brain Res Brain Res Rev. 2004 Apr;45(1):38-78
references: 15063099
references: Epilepsia. 2012 Jun;53 Suppl 1:61-6
references: 22612810
references: Am J Pathol. 2011 Apr;178(4):1509-16
references: 21435440
references: Alzheimer Dis Assoc Disord. 1987;1(4):256-62
references: 3453748
references: Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):6058-63
references: 20231476
references: Pharmacopsychiatry. 1994 Jan;27(1):11-5
references: 8159776
references: Brain Res. 1983 Nov 28;280(1):119-26
references: 6228286
references: Alzheimer Dis Assoc Disord. 1994;8 Suppl 3:54-60
references: 7999346
references: Br J Psychiatry. 1980 Jun;136:533-41
references: 6155966
references: Arch Neurol. 2006 May;63(5):686-92
references: 16533956
references: J Comp Neurol. 1989 Sep 15;287(3):373-92
references: 2570794
references: Neurochem Int. 2010 Nov;57(4):375-82
references: 20144675
references: Mult Scler. 2010 Feb;16(2):208-17
references: 20007431
references: J Neurosci. 2006 Feb 1;26(5):1343-54
references: 16452658
references: Neurobiol Dis. 2003 Dec;14(3):318-27
references: 14678749
references: J Neurosci. 2006 Dec 6;26(49):12838-46
references: 17151287
references: Ann N Y Acad Sci. 1985;444:242-54
references: 2990292
references: Alzheimer Dis Assoc Disord. 1995 Winter;9(4):233-7
references: 8749613
references: J Neurosci. 2010 Sep 1;30(35):11848-57
references: 20810904
references: Neuropathology. 2006 Dec;26(6):528-32
references: 17203588
references: Arch Neurol. 2010 Jun;67(6):707-14
references: 20558389
references: Toxicol Ind Health. 2014 Jul;30(6):551-60
references: 23024111
references: J Nerv Ment Dis. 1986 May;174(5):290-4
references: 3517228
references: J Atten Disord. 2011 Feb;15(2):130-8
references: 20026871
references: Science. 1975 Apr 25;188(4186):377-8
references: 1118734
references: J Neurosci. 2002 Apr 1;22(7):2434-42
references: 11923407
references: Prog Neurobiol. 1977;9(3):147-96
references: 202996
references: Neurobiol Aging. 2012 Feb;33(2):426.e1-11
references: 21109328
references: J Neurosci. 2006 Jan 11;26(2):467-78
references: 16407544
references: Neuropsychopharmacology. 1999 Apr;20(4):357-64
references: 10088136
references: Exp Neurol. 2012 Aug;236(2):199-206
references: 22609331
references: Arch Gen Psychiatry. 1984 Apr;41(4):343-6
references: 6703854
references: Biochem Soc Trans. 2012 Aug;40(4):711-5
references: 22817721
references: J Gerontol A Biol Sci Med Sci. 2005 Jan;60(1):67-73
references: 15741285
references: J Cereb Blood Flow Metab. 2000 Aug;20(8):1197-204
references: 10950380
references: J Neurochem. 2010 May;113(3):649-60
references: 20132474
references: Neurobiol Aging. 2010 Apr;31(4):614-24
references: 18632189
references: Neurobiol Aging. 2007 Mar;28(3):327-35
references: 16574280
references: Neurobiol Aging. 2003 Jan-Feb;24(1):1-23
references: 12493547
references: J Child Adolesc Psychopharmacol. 2005 Aug;15(4):664-70
references: 16190797
references: Brain Behav Immun. 2008 Oct;22(7):1078-1086
references: 18468841
references: Science. 2010 Dec 24;330(6012):1774
references: 21148344
references: Am J Geriatr Psychiatry. 2012 Nov;20(11):994-1000
references: 22048323
references: J Comp Neurol. 1975 Nov 15;164(2):209-31
references: 810499
references: Cell Signal. 2007 Feb;19(2):251-60
references: 16996249
references: J Neurochem. 2010 Apr;113(2):543-51
references: 20132473
references: Brain Res. 2008 May 19;1210:216-22
references: 18423577
references: Neurology. 2010 Aug 3;75(5):448-55
references: 20679638
references: Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):291-4
references: 9387890
references: Arch Neurol. 2003 Mar;60(3):337-41
references: 12633144
references: Neuroscience. 1999;92(3):975-82
references: 10426537
references: Nat Neurosci. 2000 May;3(5):465-71
references: 10769386
references: Neuroscience. 2011 Mar 10;176:396-407
references: 21129451
references: Scand J Clin Lab Invest. 2012 Sep;72(5):427-32
references: 22708640
references: Neuropharmacology. 2011 Feb-Mar;60(2-3):223-34
references: 20850464
references: PLoS One. 2011 Apr 19;6(4):e18850
references: 21526197